Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$590K Sell
2,344
-7
-0.3% -$1.51K 0.14% 87
2026
Q1
$511K Sell
2,351
-175
-7% -$38.8K 0.13% 88
2025
Q4
$577K Sell
2,526
-111
-4% -$25.3K 0.14% 86
2025
Q3
$611K Sell
2,637
-24
-0.9% -$4.89K 0.16% 83
2025
Q2
$494K Sell
2,661
-98
-4% -$18.2K 0.14% 85
2025
Q1
$578K Buy
2,759
+71
+3% +$13.8K 0.16% 82
2024
Q4
$478K Buy
2,688
+2
+0.1% +$368 0.14% 90
2024
Q3
$531K Buy
2,686
+1
+0% +$187 0.16% 87
2024
Q2
$461K Sell
2,685
-108
-4% -$17.9K 0.15% 90
2024
Q1
$509K Sell
2,793
-47
-2% -$8.1K 0.17% 88
2023
Q4
$440K Buy
2,840
+150
+6% +$21.9K 0.15% 98
2023
Q3
$401K Buy
2,690
+39
+1% +$5.72K 0.15% 104
2023
Q2
$357K Buy
2,651
+30
+1% +$4.4K 0.14% 90
2023
Q1
$418K Buy
2,621
+2
+0.1% +$306 0.17% 89
2022
Q4
$423K Sell
2,619
-16
-0.6% -$2.45K 0.17% 100
2022
Q3
$354K Hold
2,635
0.16% 97
2022
Q2
$404K Hold
2,635
0.18% 90
2022
Q1
$415K Buy
2,635
+46
+2% +$6.68K 0.18% 95
2021
Q4
$351K Hold
2,589
0.14% 105
2021
Q3
$279K Hold
2,589
0.12% 108
2021
Q2
$292K Buy
2,589
+2
+0.1% +$225 0.12% 110
2021
Q1
$280K Buy
+2,587
New +$277K 0.12% 113

Other funds holding ABBV

Navalign LLC's ABBV Position: Q2 2026 in Review

Navalign LLC reduced its AbbVie (ABBV) stake by 0.3% in Q2 2026, selling an estimated $1.51K and leaving 2,344 shares worth $590K. The position accounts for 0.14% of the portfolio, ranked #87.

Navalign LLC first reported a position in ABBV in Q1 2021 and has held it in 22 quarters since. The position peaked at $611K in Q3 2025. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Navalign LLC held 2,344 shares of AbbVie worth $590K as of Q2 2026.
  • Navalign LLC sold 7 AbbVie shares in Q2 2026, an estimated $1.51K.
  • AbbVie made up 0.14% of Navalign LLC's portfolio in Q2 2026, its #87 holding.
  • Navalign LLC first reported a position in AbbVie in Q1 2021 and has held it in 22 quarters since.
  • Navalign LLC's AbbVie position peaked at $611K in Q3 2025.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Navalign LLC's 13F filing for Q2 2026, filed 28 Jul 2026.